Impairment of the protein C anticoagulant pathway in a patient with systemic lupus erythematosus, anticardiolipin antibodies and thrombosis

Thrombosis Research
L AmerR C Williams

Abstract

We have identified an inhibitor of the protein C anticoagulant pathway in the plasma of a patient with systemic lupus erythematosus and a history of recurrent deep vein thrombosis, fetal wastage, and seizures. The patient's plasma contained anticardiolipin antibodies as well as a weak lupus anticoagulant. Examination of this patient's plasma revealed normal levels of protein C and protein S antigen, normal levels of functional protein C, as well as essentially normal levels of every blood coagulation factor. In a modified prothrombin time assay, the activated protein C-mediated prolongation of the clotting time observed in normal plasma was not observed in this patient's plasma. Gel permeation chromatography of the patient's plasma revealed that the inhibitory material was a high molecular weight protein that coeluted with the IgM peak. The inhibitor did not appear to circulate as a complex with protein C, since the inhibitor could easily be separated from protein C during fractionation procedures, and did not interfere with the activation of protein C in plasma as assessed by a functional amidolytic assay. Our findings suggest that the recurrent thrombotic episodes observed in this patient may have occurred as a result of the ...Continue Reading

References

Oct 1, 1987·Annals of the Rheumatic Diseases·M A ByronS A Cederholm-Williams
Mar 1, 1987·Thrombosis Research·F McCallJ F Davidson
Dec 24, 1987·The New England Journal of Medicine·C A MitchellH H Salem
Feb 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·Y SakataD J Loskutoff
Mar 30, 1973·Biochimica Et Biophysica Acta·W Kisiel, D J Hanahan
Mar 1, 1984·The New England Journal of Medicine·U SeligsohnS I Rapaport
Nov 1, 1983·Scandinavian Journal of Haematology·G Frantzen HandelandA O Aasen
Apr 1, 1984·The Journal of Clinical Investigation·G J Broze, J P Miletich
Nov 1, 1981·The Journal of Clinical Investigation·J H GriffinC Wideman

❮ Previous
Next ❯

Citations

Sep 1, 1996·Arthritis and Rheumatism·R A Roubey
Jan 1, 1991·Rheumatology International·A P van Dam
Nov 1, 1995·Journal of Clinical Immunology·D B Cines, K R McCrae
Mar 15, 1996·Thrombosis Research·U Nowak-GöttlH Jürgens
Nov 14, 1997·Journal of Reproductive Immunology·D S Dizon-TownsonK Ward
Feb 15, 2002·British Journal of Haematology·P Clark, I D Walker
Aug 1, 1995·British Journal of Haematology·K VáradiH P Schwarz
Dec 21, 2000·Current Rheumatology Reports·J T Merrill
Nov 1, 1996·European Journal of Pediatrics·U Nowak-GöttlB Zieger
Apr 8, 2000·Blood Cells, Molecules & Diseases·J A FernándezJ H Griffin
Dec 1, 1993·Blood Reviews·D M Keeling, D A Isenberg
Aug 1, 1994·Lupus·P G de Groot, R H Derksen
Dec 6, 2001·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·D GemmatiG L Scapoli
Oct 9, 2002·Obstetrical & Gynecological Survey·Amy M Adelberg, Jeffrey A Kuller
Jul 1, 1992·La Revue de médecine interne·L GrunebaumJ P Cazenave

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.